<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483961</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-CV-317-001</org_study_id>
    <nct_id>NCT03483961</nct_id>
  </id_info>
  <brief_title>Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults</brief_title>
  <official_title>A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PaxVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PaxVax, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of
      various doses/formulations/and schedules of administration of PXVX0317 in healthy adults.

      Primary Objective:

      To assess the immune response to the vaccine

      Secondary Objectives:

      To assess the kinetics of the immune response to different doses/formulations/schedules To
      assess the persistence of immune responses to different doses/formulations/schedules To
      assess the effect of a booster dose of the vaccine

      Safety Objective:

      To assess local and systemic reactions to the vaccine and to describe the safety profile of
      the vaccine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will explore 8 formulation/schedule combinations of CHIKV VLP vaccine with or
      without Alhydrogel adjuvant, and will also explore different dose schedules of Day 1 and 15
      or Day 1 and 29 or Day 29 only.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-CHIKV neutralizing antibody response 28 days after the last injection</measure>
    <time_frame>57 days (From day 1 vaccination)</time_frame>
    <description>To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody responses by different formulations and schedules, as measured at 28 days after the last injection (Day 57).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics of anti-chikungunya virus (CHIKV) neutralizing antibody response</measure>
    <time_frame>Kinetics will be measured from 7 days after the first injection (Day 8) to 28 days after the last injection (Day 57).</time_frame>
    <description>To describe the kinetics of induction of anti-CHIKV neutralizing antibody responses by different formulations and schedules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the difference in persistence of neutralizing antibody responses</measure>
    <time_frame>Neutralizing antibody levels will be measured up to Day 547</time_frame>
    <description>To assess the difference in persistence of neutralizing antibody responses induced by different formulations and schedules, as measured up to 518 days after the last injection (Day 547) relative to earlier time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boosting of vaccine-induced neutralizing antibody responses by a booster dose of PXVX0317</measure>
    <time_frame>Antibody levels will be measured at Days 547 prior to the booster dose and again 28 days later on Day 575.</time_frame>
    <description>To assess the effect of a booster dose of PXVX0317 on neutralizing antibody levels when given at Day 547. Antibody levels will be measured at Days 547 prior to the booster dose and again 28 days later on Day 575.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of vaccine-related reactions and adverse events</measure>
    <time_frame>Local and systemic reactions will be assessed for 7 days following each injection. Adverse events will be followed for 730 days.</time_frame>
    <description>Local and systemic solicited adverse events will be recorded following each vaccination. Unsolicited adverse events will be collected for 28 days after each vaccination, and serious adverse events will be collected throughout the study. The frequencies and percentages of subjects in each study group (of the 8 formulations/schedules being studied) experiencing each solicited adverse event will be analyzed. Treatment-emergent adverse events will be analyzed by group.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chikungunya Virus Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIKV VLP/unadjuvanted</intervention_name>
    <description>Vaccine consists of virus-like particles of chikungunya virus antigens</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIKV VLP/adjuvanted</intervention_name>
    <description>Adjuvanted formulation includes Alhydrogel</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is vaccine diluent alone</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female

          2. Age 18 to 45 years old (inclusive)

          3. Using an acceptable method of contraception (if female of childbearing potential).

          4. Able and willing to provide informed consent for study participation.

        Exclusion Criteria:

          1. Current acute febrile illness.

          2. Clinically significant cardiac, respiratory, or rheumatologic disease, in the opinion
             of the Investigator.

          3. Pregnant or breast-feeding.

          4. Laboratory evidence of infection with Hepatitis B/C or HIV.

          5. History of chikungunya virus infection.

          6. Travel to a World Health Organization-designated chikungunya-endemic region within 30
             days prior to Day 1.

          7. History of allergic reaction to any component of CHIKV-VLP vaccine, Diluent, or
             Alhydrogel®.

          8. Inability to discontinue systemic immunomodulatory or immunosuppressive medications 30
             days prior to Day 1.

          9. Received or plans to receive any licensed vaccine from 30 days prior to Day 1 through
             Day 57.

         10. Received or plans to receive an investigational agent from 30 days prior to Day 1
             through the duration of study participation.

         11. Any other condition that, in the opinion of the Investigator, creates an unacceptable
             risk to the subject.

         12. Any other condition that, in the opinion of the Investigator, may interfere with the
             conduct of the study or the validity of the data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Bennett, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>PaxVax, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hemamalini Vairamuthu</last_name>
    <phone>650 257 2452</phone>
    <email>hvairamuthu@paxvax.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

